Spinal Muscular Atrophy
Biogen Canada Inc.
Call for patient/clinician input open:
Call for patient/clinician input closed:
Manufacturer Requested Reimbursement Criteria1:
Biogen Canada Inc. requests that the previous CADTH-recommended criteria (see project SR0576-000) for Spinraza be expanded to include adult type II & type III patients older than 18 years of age regardless of ambulatory status.
Spinraza (nusinersen) is indicated for the treatment of 5q Spinal Muscular Atrophy (SMA).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.